Clinical Trials Browser

Phase 1 × OTHER × palbociclib × Clear all

NCT06113809 2026-05-22

Palbociclib and Pembrolizumab in Sarcoma

Phase 1 Recruiting

Sarcoma

NCT04996160 2026-04-17

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase 1 Suspended

GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1 Completed

Lung Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT03472573 2025-05-15

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1 Completed

Burkitt Lymphoma

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT03900884 2024-11-07

PALVEN

Phase 1 Active not recruiting

Breast Neoplasm Female

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

Breast Neoplasms

NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04483505 2023-12-28

ROGABREAST

Phase 1 Completed

BreastOther neoplasm

Breast Cancer Metastatic

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06065592 2023-10-06

CAT_PB

Phase 1 Unknown

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04872608 2023-04-28

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03128619 2022-09-26

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

Breast Neoplasms

NCT01976169 2022-02-08

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Phase 1 Completed

Breast Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03515200 2020-09-01

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01320592 2020-04-08

PD0332991/Paclitaxel in Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01522989 2020-03-04

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Phase 1 Unknown

Neoplasms

NCT01111188 2019-06-27

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Phase 1 Terminated

Lymphoma, Mantle-Cell

NCT02030483 2018-08-22

PD + RD

Phase 1 Terminated

Multiple Myeloma